Media

The AIDS Clinical Trials Group (ACTG) was initially established in 1987 to broaden the scope of the AIDS research effort of the National Institute of Allergy and Infectious Diseases (NIAID). The ACTG established and supports the largest Network of expert clinical and translational investigators and therapeutic clinical trials units in the world, including sites in resource-limited countries. These investigators and units serve as the major resource for HIV/AIDS research, treatment, care and training/education in their communities.

Jeff Taylor, Community Representative from the AMC with Dr. Joel Palefsky, from University of California, San Francisco and chair of AMCs Human Papillomavirus Working Group discusses an overview HPV as this is the most common sexually transmitted disease, causing most of the cancers of the anus and cervix. Studies done have changed the way in which patients with HIV and HPV-associated disease are treated.

Jeff Taylor, Community Representative from the AMC with Dr. Joel Palefsky, from University of California, San Francisco and chair of AMCs Human Papillomavirus Working Group discusses new methods of prevention and treatment of anal and cervical cancers and cancer precursors in HIV-positive patients.

Jeff Taylor, Community Representative the AMC with Dr. Ariela Noy, attending physician at Memorial Sloan Kettering Cancer Center in New York and chair of AMCs Lymhpoma Working Group discusses the purpose of the working group and the type of research that has been done.

James Why, Community Representative the AMC with Dr. John Deeken, Assistant Professor at Georgetown University School of Medicine, Department of Oncology discusses the NON-Aids defining cancer working group and finding there's a rising epidemic of cancer and HIV positive patients in cancers not associated with the HIV epidemic.

Patient Navigators: Christine Desay, at UCLA Care Clinic and Jorge Vasquez at UCSD discuss their current successes, experiences and challenges in assisting individuals with HIV / AIDs diagnosis.

The Rectal Revolution is Here: An introduction to rectal microbicide clinical trials" discusses the critical need for new methods to prevent the sexual transmission of HIV - in this case rectal microbicides - and explains the clinical trial process.

Ronald Mitsuyasu, MD is a practicing physician, specializing in Oncology and Hematology. Dr. Mitsuyasu is also Director, of the CARE Center, Professor in Residence, Department of Medicine, Hematology/Oncology at UCLA, Associate Director for Clinical Programs, UCLA AIDS Institute, and Member, JCCC Tumor Immunology Program Area. 

Dr. Mitsuyasu discusses current research topics including AIDS oncology, the cure, and various experimental methods aimed at manipulating viral behavior.

Jeff Taylor of HIV + Aging Research Project | PS interviews Tim Wilkin of Cornell Medical Center and Ronald Mitsuyasu from the Department of Medicine, Hematology/Oncology at UCLA to discuss HIV Malignancies.

Jeff Taylor of HIV + Aging Research Project | PS interviews Tim Wilkin of Cornell Medical Center and Margaret Borok of Zimbabwe University at the CROI in Boston.

Men who have anal sex with men (MSM) are more likely to get anal HPV than men who only have sex with women. Researchers estimate that the prevalence of anal HPV among men who only have sex with women is around 15% while anal HPV prevalence for MSM is around 60%. If you add HIV into the mix, infection risk goes up still—one study published by HIV Medicine found that 77% of MSM with HIV were also infected with anal HPV; another study published by the Journal of Infectious Diseases found that over 90% of MSM with HIV were infected with at least one strain of HPV.

This increased risk extends to the strains of HPV known to cause cancer, with about a third of MSM living with HIV shown to have HPV type 16. MSM with HIV are also more likely to go on to develop anal cancer, with incidence rates per person-years as high as five times that of HIV-negative MSM. According to the CDC, men who have sex with men are about 17 times more likely to develop anal cancer than men who only have sex with women.

Dr. Kevin De Cock, Chair of the 20th CROI, introduces IFARA's CROI Treatment Update Series.

Each year IFARA (AccessHIV) conducts 40 Interviews and Panels at the Conference on RetroViruses and Opportunistic Infections as part of the Treatment Update - some of the latest information on HIV/AIDS. Antiviral / Anti-retroviral Therapies , Hepatitis, and Metabolics, Aging, The Cure, Women in Research, African American Women and HIV, and many more!